Age at menarche and near final height after treatment with gonadotropin-releasing hormone agonist alone or combined with growth hormone in Korean girls with central precocious puberty

Gyon, YunHee; Yun, Yeong Ju; Kim, Yong‐Dae; Han, Heon-Seok

doi:10.1297/cpe.24.175

Cited by 13 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this drug is expensive, and its cost is particularly high when combined with rhGH. In addition, improvements in final adult height (FAH) in CPP greatly varies [ 3 – 5 ].…”

Section: Introductionmentioning

confidence: 99%

GnRH agonist treatment for idiopathic central precocious puberty can improve final adult height in Chinese girls

et al. 2017

View full text Add to dashboard Cite

ObjectTo study the outcomes of GnRHa on final adult height in Chinese idiopathic central precocious puberty (ICPP) girls and the involved factor(s) that can predict height gain.MethodsWe conducted a retrospective analysis on 10 years of data obtained from three clinical hospitals from January 2005 to March 2015, and 101 girls with ICPP, who received GnRHa therapy for more than six months and already reached their adult height were enrolled.ResultsHeight, bone age, midparent height, HtSDS, sexual development, therapy duration and predicted adult height(PAH)at start and end of GnRHa, and the final adult height(FAH) were recorded and calculated. Their PAH significantly increased at end of GnRHa (158.4±6.00cm), compared to that at the start of GnRHa(153.1±5.37cm) (P<0.001), and their final adult height(157.0±4.82) significantly increased compared to PAH at start of GnRHa(P<0.001). There was no difference between PAH at end of GnRHa and FAH(P>0.05). After GnRHa therapy, most of the ICPP girls reached their midparent height compared to that at start of GnRHa(P<0.01). FAH was positively correlated with Ht at start, and end of GnRHa, PAH at start and end of GnRHa, and also with midparent height (R2=0.59, 0.74, 0.68, 0.73 and 0.80, P<0.001). While FAH was not correlated with the duration of treatment and BA at start of GnRHa(R2 = 0.15and 0.1, P>0.05). The percentage of adult short stature decreased and those reached midparent height significantly increased after GnRHa therapy, compared to that at start of GnRHa(60.6% vs.30.4% and 67.85% vs. 94.64%, respectively, P<0.05).ConclusionsGnRHa therapy to ICPP girls can effectively achieve the final adult height. After GnRHa therapy, most of these patients reached their midparent height, while few of these patients had an adult short stature.

show abstract

“…However, this drug is expensive, and its cost is particularly high when combined with rhGH. In addition, improvements in final adult height (FAH) in CPP greatly varies [ 3 – 5 ].…”

Section: Introductionmentioning

confidence: 99%

GnRH agonist treatment for idiopathic central precocious puberty can improve final adult height in Chinese girls

et al. 2017

View full text Add to dashboard Cite

show abstract

“…For girls with CPP who show a marked decrease in GV, evidence indicates that the addition of rhGH to GnRHa is significantly more effective in improving height, and PAH than GnRHa alone 12 . One very recent study published in 2015 reported the combined treatment group showed a greater height increment during treatment in Korean girls compared to the GnRHa alone group 46 . In 2003, Pucarelli and colleagues 47 found that the height gain in the combined treatment group was 6 cm higher than the GnRHa alone group.…”

Section: Discussionmentioning

confidence: 96%

The Efficacy of GnRHa Alone or in Combination with rhGH for the Treatment of Chinese Children with Central Precocious Puberty

Wang

Zhang

Lan

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The addition of recombinant human growth hormone (rhGH) to GnRH agonist (GnRHa) to treat central precocious puberty (CPP) is controversial. We systemically reviewed and evaluated the efficacy and safety of the rhGH and GnRHa adjunctive therapy in Chinese children with CPP and assessed the influence of age and therapy duration on the efficacy of the combined treatment. A total of 464 patients were included from 14 studies. Compared with baseline, administration of GnRHa plus rhGH led to a significant increase in height, predicted adult height (PAH) and height standard deviation for bone age (HtSDS-BA), corresponding to a weighted mean difference (WMD) (95%CI) of 9.06 cm (6.41, 11.70), 6.5 cm (4.47, 8.52), and 0.86 (0.58, 1.14) respectively. Subgroup analysis showed the combined therapy had increased efficacy in subjects with initial treatment age younger than 10 years old or with treatment lasting over 12 months. Compared with GnRHa alone treatment, the combined treatment led to a significant increase in height, PAH and HtSDS-BA, corresponding to a WMD (95% CI) of 3.56 cm (2.54, 4.57), 3.76 cm (3.19, 4.34) and 0.56 (0.43, 0.69). The combined treatment exhibited no safety concerns. Our findings may aid clinicians in making treatment decisions for children with CPP.

show abstract

“…In previous other studies, Partsch et al [ 22 ] reported that initial BA advancement and treatment duration were factors that explained 68% of height gain. Other studies found that MPH, CA, pretreatment height, height at the end of treatment, and growth rate during treatment were factors influencing near final height [ 23 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty

Kim

Nam

Rhie

et al. 2017

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

Purpose This study investigated the influence of obesity on the clinical course and effect of gonadotropin-releasing hormone analog (GnRHa) treatment in girls with central precocious puberty (CPP).Methods Medical records of 182 girls with CPP treated with GnRHa were reviewed. They were divided into 2 groups: normal weight (n=108) and overweight/obesity (n=74). Chronological age (CA), bone age (BA), difference between BA and CA (BA–CA), standard deviation score (SDS) of height, body mass index (BMI), predicted adult height (PAH), and laboratory findings were compared at baseline, after 1 year, and at the end of GnRHa treatment in both groups.Results Mean BMI SDS at baseline was 0.08±0.60 in the normal weight group and 1.55±0.36 in the overweight/obesity group. Initial CA, BA, midparental height, and PAH were similar between the 2 groups. BA–CA after treatment was significantly decreased compared to baseline in both groups (P<0.001). Between the 2 groups, a decrease in BA–CA during treatment showed no significant difference. PAH at the end of treatment was significantly increased compared to baseline in both groups (P<0.001). PAH at the end of treatment in the overweight/obesity group (159.88±3.41 cm) was similar to that of the normal weight group (159.19±3.25 cm). Comparing the 2 groups according to change in BMI after treatment, there were no differences in ΔPAH, ΔBA–CA, and Δheight SDS for BA.Conclusions GnRHa treatment in obese girls with CPP improved the height outcome and had similar results in normal weight CPP girls. Obesity might not affect the efficacy of GnRHa in girls with CPP.

show abstract

Age at menarche and near final height after treatment with gonadotropin-releasing hormone agonist alone or combined with growth hormone in Korean girls with central precocious puberty

Cited by 13 publications

References 18 publications

GnRH agonist treatment for idiopathic central precocious puberty can improve final adult height in Chinese girls

GnRH agonist treatment for idiopathic central precocious puberty can improve final adult height in Chinese girls

The Efficacy of GnRHa Alone or in Combination with rhGH for the Treatment of Chinese Children with Central Precocious Puberty

Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty

Contact Info

Product

Resources

About